News | January 08, 2009

Bayer Schering Pharma Deal Targets Molecular Imaging

January 8, 2009 – Bayer Schering Pharma AG and Hamamatsu Photonics K.K., Japan have signed a licensing agreement for the use of novel substances in the field of molecular imaging for cancer, allowing the company to expand its existing molecular imaging portfolio in the area of cancer.

In the agreement, Bayer Schering Pharma acquires the worldwide exclusive rights for research, development and commercialization of a group of molecules that specifically bind to malignant tumor cells. The company anticipates that used in combination with positron emission tomography (PET), these tracers could potentially improve the diagnosis of a variety of cancers.

The tracers are labeled with a short-life radionuclide and thus can be employed for PET imaging. PET is a nuclear medicine imaging procedure, with which molecular processes can be visualized in vivo, for example those in tumor cells. In contrast to the presently common procedures in PET imaging of cancer, these new PET tracers could help to possibly better differentiate malignant tumors from benign tissue alterations and to allow a more precise staging of the cancer.

"We have developed the novel tumor PET tracer based on a substance to be incorporated into tumor cells through the carrier molecules highly expressed on the tumor cell membrane. Since the chemical structure of this PET tracer is designed not to be identified by the carrier system on the normal cell membrane, the location of tumor tissue could be detected with high contrast in tumor animal models with PET,” said Hideo Tsukada, M.D., manager of the PET Center at Hamamatsu Photonics.

Find more information: www.bayerhealthcare.com

Related Content

The Global Contrast Injectors Market will grow by $613.47M during 2020-2024, according to Technavio
News | Contrast Media Injectors | June 17, 2020
June 17, 2020 — Technavio has been monitoring the ...
The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease

Getty Images

News | Contrast Media | June 01, 2020
June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for...
Researchers from Tokyo Metropolitan University have surveyed the amount of gadolinium found in river water in Tokyo. Gadolinium is contained in contrast agents given to patients undergoing medical magnetic resonance imaging (MRI) scans, and it has been shown in labs to become toxic when exposed to ultraviolet rays. The researchers found significantly elevated levels, particularly near water treatment plants, highlighting the need for new public policy and removal technologies as MRI become even more commonp

Samples were taken along rivers around Tokyo. Measurements of rare earth element quantities indicate a clearly elevated amount of gadolinium compared to that in natural shale. Graphics courtesy of Tokyo Metropolitan University

News | Magnetic Resonance Imaging (MRI) | May 26, 2020
May 26, 2020 — Researchers from Tokyo Metropolitan...
Gadolinium-based contrast agents

UT Dallas faculty members who collaborated with Dr. Jeremiah Gassensmith (center, back), associate professor of chemistry and biochemistry, include Dr. Lloyd Lumata (left, back), assistant professor of physics, and Dr. Steven Nielsen, associate professor of chemistry. Chemistry graduate students in Gassensmith’s lab include (from left, front) Oliva Brohlin, Arezoo Shahrivarkevishahi and Laurel Hagge.

News | Contrast Media | February 06, 2020
February 6, 2020 — University of Texas at Dallas researchers
Gadolinium based contrast dye in brain MRI

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | January 17, 2020
January 17, 2020 — Bracco Diagnostics Inc., the U.

Guerbet presented its Contrast&Care injection management solution at ECR 2018

News | Contrast Media | November 13, 2019
November 13, 2019 – Guerbet, a global specialist in...